Lymphatic System News and Research

RSS

Lymph is clear or white fluid that travels through vessels, moves within tissues and work to keep all the parts of the body clean.
After passing through the channels of the lymphatic system they drain into the lymph nodes.
The lymph nodes act as filters along the lymphatic system. These nodes trap germs like bacteria, viruses, toxins as well as cancer cells and ensure that these are removed from the body.

Transgenic mice to visualize metastasis and inflammation

One of the major routes of tumor cell dissemination to form metastasis at distant organs in the body is the lymphatic system. To study this process, still poorly understood, and to gain information on which tumors prefer this route for dissemination and how to block it, researchers of the Spanish National Cancer Research Center, led by researcher Sagrario Ortega, have created transgenic mice in which, for the first time, the growth of the lymphatic vessels can be visualized in the whole animal, by a light-emitting reaction, as tumor progresses and forms metastasis.

3 Apr 2012

InflammaGen Therapeutics initiates Shok-Pak Phase 2 pilot study

InflammaGen Therapeutics, a development-stage, critical care company initially focused on the diagnosis, treatment and prevention of multi-organ failure (MOF), announced today that the Company has initiated a 200-patient Phase 2 pilot study to examine the efficacy and safety of InflammaGen Shok-Pak as a potential treatment for critically ill patients in the Intensive Care Unit.

12 Mar 2012

InflammaGen to initiate Phase 2 study of new drug/delivery platform for shock

A 200-patient Phase 2 clinical pilot study will be initiated this month to test the efficacy and safety of a new use, and method of administering, an enzyme inhibitor for critically ill patients developed by University of California, San Diego Bioengineering Professor Geert Schmid-Sch-nbein. Conditions expected to qualify for the study include new-onset sepsis and septic shock, post-operative complications, and new-onset gastrointestinal bleeding.

12 Mar 2012

Vemurafenib nearly doubles survival for patients with metastatic melanoma

Investigators from Vanderbilt-Ingram Cancer Center (VICC) and 12 other centers in the United States and Australia have found that a new drug for patients with metastatic melanoma nearly doubled median overall survival.

23 Feb 2012

EMA CHMP recommends CTI's Pixuvri for conditional approval

Cell Therapeutics, Inc. announced today that Pixuvri has been granted a positive opinion for conditional approval from the European Medicines Agency's Committee for Medicinal Products for Human Use.

18 Feb 2012

Tissues in SIV-infected monkeys can ramp up production of Tregs

Tissue in monkeys infected with a close relative of HIV can ramp up production of a type of T cell that actually weakens the body's attack against the invading virus. The discovery, in lymph nodes draining the intestinal tract, could help explain how the HIV virus evades the body's immune defenses.

15 Feb 2012

Lymphatic Research and Biology focuses on lymphangiomatosis, Gorham's disease

A clinically challenging and under-studied subset of diseases affecting the lymphatic system and grouped under the disease spectrum lymphangiomatosis and Gorham's disease is the focus of a special issue of Lymphatic Research and Biology, a peer-reviewed journal published by Mary Ann Liebert, Inc.

9 Feb 2012

Researchers discover new gene linked to MLCRD

Researchers have found a new gene that, when mutated, can lead to lymphoedema (swollen limbs) as part of a rare disorder that can also cause problems with eye and brain development. This is the fourth lymphoedema-related gene found by the same researchers in three years, and the first linked to the eyes and brain. They say it could lead to better diagnosis and treatment for lymphoedema, an area that has been poorly understood previously.

27 Jan 2012

FLT-PET imaging can effectively detect mantle cell lymphoma

Positron emission tomography (PET) and a molecular imaging agent that captures the proliferation of cancer cells could prove to be a valuable method for imaging a form of Non-Hodgkin's disease called mantle cell lymphoma, a relatively rare and devastating blood cancer.

22 Dec 2011

QAI announces availability of Virtual Human Body App

QA International (QAI) announced today its Virtual Human Body App for iPad is now available from the App Store. People of all ages will enjoy fingertip navigation through the 10 systems and structures of the human body, with lifelike imagery.

6 Dec 2011

Treatments for lymphoma with no side effects

Larry Conrad went in for his annual physical on his 50th birthday. During his exam, his doctor found swollen lymph nodes in his armpits and groin. Conrad had a cough and said he'd lost weight because he 'felt full all the time'. His doctor ordered a series of tests, and Conrad was diagnosed with Non-Hodgkin's lymphoma, the most common type.

2 Dec 2011

Study reveals underlying molecular mechanism contributing to development of lymphomagenesis

Researchers from the NYU Cancer Institute, an NCI-designated cancer center at NYU Langone Medical Center, have discovered a new potential therapeutic target for Diffuse Large B-Cell Lymphoma (DLBCL), the most aggressive and common type of lymphoma in adults.

29 Nov 2011

Prox1 gene plays a critical role in formation and maintenance of lymphatic system

A century after the valves that link the lymphatic and blood systems were first described, St. Jude Children's Research Hospital scientists have detailed how those valves form and identified a gene that is critical to the process.

15 Nov 2011

NIH awards $452,218 for research on proinflammatory biomarkers and post-breast cancer lymphedema

New York University College of Nursing received a two-year, $452,218.00 grant from the national Institutes of Health to research "Proinflammatory Biomarkers and Post-Breast Cancer Lymphedema."

28 Oct 2011

HCI researchers discover new way to model human breast cancer

Researchers from Huntsman Cancer Institute (HCI) at the University of Utah have discovered a new way to model human breast cancer that could lead to new tools for predicting which breast cancers will spread and new ways to test drugs that may stop its spread.

24 Oct 2011

EMA recommends 4SC's resminostat for orphan medicinal product designation to treat HL

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that the European Medicines Agency (EMA) has recommended 4SC's anti-cancer compound resminostat for designation as orphan medicinal product for the treatment of Hodgkin's Lymphoma (HL), a cancer of the lymphatic system.

13 Oct 2011

Positive topline data from 4SC's resminostat Phase II trial on Hodgkin's Lymphoma

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced positive topline data from its Phase II SAPHIRE trial with resminostat, its oral pan HDAC inhibitor, in patients with relapsed/refractory Hodgkin's Lymphoma.

6 Sep 2011

Researchers discover gene mutation linked with lymphoedema, leukaemia

Researchers have discovered a gene that when mutated can cause lymphoedema (swollen limbs due to a failure of the lymph system), immune abnormalities, deafness and leukaemia.

5 Sep 2011

Boehringer Ingelheim initiates two afatinib phase II studies in HER2-positive breast cancer

Boehringer Ingelheim today announced the initiation of two phase II studies, 1200.89 and LUX-Breast 2, evaluating afatinib in patients with metastatic breast cancer, who have an overexpression of the erbB2 (HER2) protein, so called HER2-positive patients. Afatinib is an irreversible ErbB Family Blocker, which binds to all erbB-family kinases including erbB2.

29 Aug 2011

FDA approves Seattle Genetics ADCETRIS drug to treat Hodgkin lymphoma, ALCL

Seattle Genetics, Inc. today announced that the U.S. Food and Drug Administration has granted accelerated approval of ADCETRISTM for two indications: (1) the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and (2) the treatment of patients with systemic anaplastic large cell lymphoma after failure of at least one prior multi-agent chemotherapy regimen.

20 Aug 2011